Wall Street brokerages expect Ocular Therapeutix Inc (NASDAQ:OCUL) to report $1.00 million in sales for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Ocular Therapeutix’s earnings. The lowest sales estimate is $500,000.00 and the highest is $2.00 million. Ocular Therapeutix reported sales of $650,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 53.8%. The business is scheduled to report its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Ocular Therapeutix will report full-year sales of $12.72 million for the current year, with estimates ranging from $9.18 million to $15.00 million. For the next year, analysts forecast that the firm will post sales of $56.10 million, with estimates ranging from $26.27 million to $72.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Ocular Therapeutix.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.03). Ocular Therapeutix had a negative net margin of 2,956.91% and a negative return on equity of 165.85%. The firm had revenue of $0.49 million during the quarter, compared to analyst estimates of $0.45 million.

A number of brokerages recently weighed in on OCUL. HC Wainwright reduced their target price on Ocular Therapeutix from $12.00 to $9.00 and set a “buy” rating on the stock in a report on Tuesday. Raymond James cut Ocular Therapeutix from a “strong-buy” rating to an “outperform” rating and reduced their target price for the company from $11.00 to $5.00 in a report on Tuesday. Cowen cut Ocular Therapeutix from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $13.00 to $3.00 in a report on Tuesday. Piper Jaffray Companies reduced their target price on Ocular Therapeutix to $8.00 and set a “market perform” rating on the stock in a report on Monday, May 20th. Finally, Zacks Investment Research upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Thursday, May 16th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.18.

In related news, Director Richard L. Md Lindstrom acquired 56,441 shares of Ocular Therapeutix stock in a transaction on Wednesday, March 13th. The shares were bought at an average price of $4.33 per share, for a total transaction of $244,389.53. Following the completion of the purchase, the director now directly owns 100,000 shares in the company, valued at approximately $433,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey S. Heier acquired 24,000 shares of Ocular Therapeutix stock in a transaction on Friday, March 15th. The shares were bought at an average price of $4.15 per share, for a total transaction of $99,600.00. Following the purchase, the director now owns 24,000 shares of the company’s stock, valued at $99,600. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 90,441 shares of company stock worth $385,490. 16.10% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of OCUL. BNP Paribas Arbitrage SA acquired a new position in shares of Ocular Therapeutix during the first quarter worth about $30,000. JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth about $50,000. JPMorgan Chase & Co. lifted its stake in shares of Ocular Therapeutix by 106.8% in the first quarter. JPMorgan Chase & Co. now owns 17,640 shares of the biopharmaceutical company’s stock worth $70,000 after acquiring an additional 9,110 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of Ocular Therapeutix by 100.0% in the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 20,000 shares of the biopharmaceutical company’s stock worth $79,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of Ocular Therapeutix by 197.0% in the fourth quarter. Bank of America Corp DE now owns 26,271 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 17,425 shares in the last quarter. Institutional investors own 47.33% of the company’s stock.

Ocular Therapeutix stock traded up $0.18 during midday trading on Monday, reaching $2.64. The stock had a trading volume of 896,505 shares, compared to its average volume of 544,770. Ocular Therapeutix has a twelve month low of $2.35 and a twelve month high of $8.28. The stock has a market capitalization of $113.09 million, a P/E ratio of -1.68 and a beta of 1.80. The company has a current ratio of 9.19, a quick ratio of 9.16 and a debt-to-equity ratio of 2.17.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Featured Article: Why are percentage gainers important?

Get a free copy of the Zacks research report on Ocular Therapeutix (OCUL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.